Helping mothers and babies, from conception to birth
At Ferring, we are committed to helping people become parents and to keeping mothers and babies healthy, from conception to birth. Over one third of our research and development investment goes towards finding innovative treatments in reproductive medicine and maternal health. We are also passionate about making a difference to people’s health and quality of life through our work in gastroenterology and orthopaedics.
Believing in the power of research
Each of us at Ferring contribute to providing innovative solutions to help people live better lives. We devote significant research and development investment to new therapeutics, life cycle management and next generation healthcare solutions.
At Ferring Pharmaceuticals we highly value an attractive working environment that motivates our employees and stimulates the creative abilities and initiative of both individuals and teams. With over 6,000 employees in 56 countries, we are able to draw upon a large multicultural setting to enrich the work of our staff on all levels.
Helping people live better lives
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and orthopaedics. Ferring has been developing treatments for mothers and babies for over 50 years.
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic-
Vaccines and Related Biological Products Advisory Committee will hold meeting on September 22, 2022 RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to r...
Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic-
New subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660. Data adds to the growing body of ev...
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022-
Parsippany, NJ – May 11, 2022 – Ferring Pharmaceuticals today announced they will present data from analyses of RBX2660, an investigational microbiota-based live biotherapeutic for reduction of rec...